Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype.

Van Bockstal M, Lambein K, Denys H, Braems G, Nuyts A, Van den Broecke R, Cocquyt V, De Wever O, Libbrecht L.

Virchows Arch. 2014 Sep;465(3):275-89. doi: 10.1007/s00428-014-1609-3. Epub 2014 Jun 29.

PMID:
24973889
2.

Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.

Lambein K, Van Bockstal M, Vandemaele L, Van den Broecke R, Cocquyt V, Geenen S, Denys H, Libbrecht L.

Virchows Arch. 2017 Nov;471(5):575-587. doi: 10.1007/s00428-017-2161-8. Epub 2017 May 31.

PMID:
28567637
3.

Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.

Afzal M, Amir M, Hassan MJ, Hussain MS, Aziz MN, Murad S, Murtaza I, Anees M, Sultan A.

Tumour Biol. 2016 Jul;37(7):8665-72. doi: 10.1007/s13277-015-4657-7. Epub 2016 Jan 6. Erratum in: Tumour Biol. 2016 Sep 30;:.

PMID:
26738861
5.

HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component.

Liao N, Zhang GC, Liu YH, Li XR, Yao M, Xu FP, Li L, Wu YL.

Pathol Res Pract. 2011 Jan 15;207(1):1-7. doi: 10.1016/j.prp.2010.08.005. Epub 2010 Nov 20.

PMID:
21095069
6.

Molecular phenotypes of DCIS predict overall and invasive recurrence.

Williams KE, Barnes NL, Cramer A, Johnson R, Cheema K, Morris J, Howe M, Bundred NJ.

Ann Oncol. 2015 May;26(5):1019-25. doi: 10.1093/annonc/mdv062. Epub 2015 Feb 12.

PMID:
25678586
7.
8.

The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.

Borgquist S, Zhou W, Jirström K, Amini RM, Sollie T, Sørlie T, Blomqvist C, Butt S, Wärnberg F.

BMC Cancer. 2015 Jun 11;15:468. doi: 10.1186/s12885-015-1479-3.

9.

Gene amplification in ductal carcinoma in situ of the breast.

Burkhardt L, Grob TJ, Hermann I, Burandt E, Choschzick M, Jänicke F, Müller V, Bokemeyer C, Simon R, Sauter G, Wilczak W, Lebeau A.

Breast Cancer Res Treat. 2010 Oct;123(3):757-65. doi: 10.1007/s10549-009-0675-8. Epub 2009 Dec 22.

PMID:
20033484
10.

Comparison of the 2007 and 2013 ASCO/CAP evaluation systems for HER2 amplification in breast cancer.

Pu X, Shi J, Li Z, Feng A, Ye Q.

Pathol Res Pract. 2015 Jun;211(6):421-5. doi: 10.1016/j.prp.2014.09.010. Epub 2014 Nov 7.

11.

Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.

Karlsson E, Sandelin K, Appelgren J, Zhou W, Jirström K, Bergh J, Wärnberg F.

Eur J Cancer. 2014 Feb;50(3):517-24. doi: 10.1016/j.ejca.2013.10.020. Epub 2013 Nov 22.

PMID:
24275214
12.

[Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].

Yang M, Xu SP, Ao QL.

Zhonghua Bing Li Xue Za Zhi. 2013 Apr;42(4):257-61. doi: 10.3760/cma.j.issn.0529-5807.2013.04.010. Chinese.

PMID:
23928534
13.

Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.

Donaldson AR, Shetty S, Wang Z, Rivera CL, Portier BP, Budd GT, Downs-Kelly E, Lanigan CP, Calhoun BC.

Cancer. 2017 Jun 15;123(12):2230-2239. doi: 10.1002/cncr.30592. Epub 2017 Feb 13.

PMID:
28192599
14.

Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?

Bethune GC, Pettit AS, Veldhuijzen van Zanten D, Barnes PJ.

Histopathology. 2017 May;70(6):966-974. doi: 10.1111/his.13160. Epub 2017 Feb 24.

PMID:
28032917
15.

Gene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based method.

Sapino A, Maletta F, Verdun di Cantogno L, Macrì L, Botta C, Gugliotta P, Scalzo MS, Annaratone L, Balmativola D, Pietribiasi F, Bernardi P, Arisio R, Viberti L, Guzzetti S, Orlassino R, Ercolani C, Mottolese M, Viale G, Marchiò C.

Oncologist. 2014 Nov;19(11):1118-26. doi: 10.1634/theoncologist.2014-0195. Epub 2014 Oct 16.

17.

HER2 immunohistochemistry significantly overestimates HER2 amplification in uterine papillary serous carcinomas.

Mentrikoski MJ, Stoler MH.

Am J Surg Pathol. 2014 Jun;38(6):844-51. doi: 10.1097/PAS.0000000000000182.

PMID:
24698965
18.

Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast.

Daoud SA, Ismail WM, Abdelhamid MS, Nabil TM, Daoud SA.

Asian Pac J Cancer Prev. 2016;17(8):3733-6.

19.

Characterization of HER2 gene amplification heterogeneity in invasive and in situ breast cancer using bright-field in situ hybridization.

Polónia A, Oliveira G, Schmitt F.

Virchows Arch. 2017 Nov;471(5):589-598. doi: 10.1007/s00428-017-2189-9. Epub 2017 Jul 13.

PMID:
28702778
20.

Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.

Elsarraj HS, Hong Y, Valdez KE, Michaels W, Hook M, Smith WP, Chien J, Herschkowitz JI, Troester MA, Beck M, Inciardi M, Gatewood J, May L, Cusick T, McGinness M, Ricci L, Fan F, Tawfik O, Marks JR, Knapp JR, Yeh HW, Thomas P, Carrasco DR, Fields TA, Godwin AK, Behbod F.

Breast Cancer Res. 2015 Sep 17;17:128. doi: 10.1186/s13058-015-0630-z.

Supplemental Content

Support Center